Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia

Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose-limiting toxicities. With the recent success of CD 19 CAR in pediatric patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalabi, Haneen, Angiolillo, Anne, Fry, Terry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589648/
https://www.ncbi.nlm.nih.gov/pubmed/26484338
http://dx.doi.org/10.3389/fped.2015.00080
_version_ 1782392818826739712
author Shalabi, Haneen
Angiolillo, Anne
Fry, Terry J.
author_facet Shalabi, Haneen
Angiolillo, Anne
Fry, Terry J.
author_sort Shalabi, Haneen
collection PubMed
description Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose-limiting toxicities. With the recent success of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this mode of therapy has become a very attractive option for these patients with high-risk disease. In this review, we will discuss current treatment paradigms of pediatric acute leukemia and potential therapeutic targets for additional high-risk populations, including T cell ALL, AML, and infant ALL.
format Online
Article
Text
id pubmed-4589648
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45896482015-10-19 Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Shalabi, Haneen Angiolillo, Anne Fry, Terry J. Front Pediatr Pediatrics Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose-limiting toxicities. With the recent success of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this mode of therapy has become a very attractive option for these patients with high-risk disease. In this review, we will discuss current treatment paradigms of pediatric acute leukemia and potential therapeutic targets for additional high-risk populations, including T cell ALL, AML, and infant ALL. Frontiers Media S.A. 2015-10-01 /pmc/articles/PMC4589648/ /pubmed/26484338 http://dx.doi.org/10.3389/fped.2015.00080 Text en Copyright © 2015 Shalabi, Angiolillo and Fry. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Shalabi, Haneen
Angiolillo, Anne
Fry, Terry J.
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title_full Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title_fullStr Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title_full_unstemmed Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title_short Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
title_sort beyond cd19: opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589648/
https://www.ncbi.nlm.nih.gov/pubmed/26484338
http://dx.doi.org/10.3389/fped.2015.00080
work_keys_str_mv AT shalabihaneen beyondcd19opportunitiesforfuturedevelopmentoftargetedimmunotherapyinpediatricrelapsedrefractoryacuteleukemia
AT angiolilloanne beyondcd19opportunitiesforfuturedevelopmentoftargetedimmunotherapyinpediatricrelapsedrefractoryacuteleukemia
AT fryterryj beyondcd19opportunitiesforfuturedevelopmentoftargetedimmunotherapyinpediatricrelapsedrefractoryacuteleukemia

Ejemplares similares